Interact to see
Advertisement
Advertisement
FSPHX vs RYCFX
FSPHX vs RYCFX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
VS
FSPHX vs. RYCFX commentary
Jul 03, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSPHX is a Buy and RYCFX is a Buy.
FUNDAMENTALS
Fundamentals
FSPHX has more cash in the bank: 5.92B vs. RYCFX (83.4M). FSPHX pays higher dividends than RYCFX: FSPHX (0.02) vs RYCFX (0.00). FSPHX was incepted earlier than RYCFX: FSPHX (44 years) vs RYCFX (24 years). RYCFX (2.43) is less costly to investors than FSPHX (0.63). RYCFX is a more actively managed with annual turnover of: 51.00 vs. FSPHX (40.00). FSPHX has a lower initial minimum investment than RYCFX: FSPHX (0) vs RYCFX (2500). FSPHX annual gain was more profitable for investors over the last year : -10.31 vs. RYCFX (-21.37). FSPHX return over 5 years is better than : -15.33 vs. RYCFX (-44.68).
| FSPHX | RYCFX | FSPHX / RYCFX | |
| Total Expense Ratio | 0.63 | 2.40 | 26% |
| Annual Report Gross Expense Ratio | 0.63 | 2.43 | 26% |
| Fund Existence | 44 years | 24 years | - |
| Gain YTD | -5.651 | -1.157 | 488% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 5.92B | 83.4M | 7,102% |
| Annual Yield % from dividends | 0.02 | 0.00 | - |
| Returns for 1 year | -10.31 | -21.37 | 48% |
| Returns for 3 years | -0.45 | -14.12 | 3% |
| Returns for 5 years | -15.33 | -44.68 | 34% |
| Returns for 10 years | 8.71 | -53.60 | -16% |
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RMFCX | 59.07 | 0.10 | +0.17% |
| American Funds American Mutual R3 | |||
| DREGX | 41.39 | N/A | N/A |
| Driehaus Emerging Markets Growth Inv | |||
| GSSQX | 64.68 | N/A | N/A |
| Goldman Sachs US Equity Insights A | |||
| DMCVX | 31.48 | N/A | N/A |
| BNY Mellon Opportunistic Midcap Value A | |||
| HLHIX | 27.57 | N/A | N/A |
| Virtus KAR Health Sciences Inst | |||